Search
for
Sort by
Research 30 of 79
- The Dark Side of 5α-Reductase Inhibitors' Therapy: Sexual Dysfunction, High Gleason Grade Prostate Cancer and Depression
- MP38-07 VASCULAR, NEUROLOGIC AND HORMONAL ABNORMALITIES IN MEN WITH PERSISTENT SEXUAL DYSFUNCTION AFTER DISCONTINUATION OF FINASTERIDE
- Female sexuality and common sexual dysfunctions: evaluation and management in a primary care setting
- Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation
- Sessualità e sindrome dell’ovaio policistico
- Benign Prostatic Hyperplasia and Sexual Dysfunction: Review of the Impact of New Medical and Surgical Therapies on Sexual Health
- Sexual Dysfunction Related to Drugs: a Critical Review. Part V: α-Blocker and 5-ARI Drugs
- Persistent Sexual Dysfunction and Suicidal Ideation in Young Men Treated with Low-Dose Finasteride: A Pharmacovigilance Study
- Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction
- Finasteride, not tamsulosin, increases severity of erectile dysfunction and decreases testosterone levels in men with benign prostatic hyperplasia
- REPORTS: Summary of the Recommendations on Sexual Dysfunctions in Women
- Testosterone therapy for sexual dysfunction in postmenopausal women
- Treatment of female sexual dysfunction in postmenopausal women—What is the evidence?
- Association Between Androgenetic Alopecia Severity and Sexual Dysfunction in Male and Female Patients Attending a Dermatology Clinic: An Exploratory Cross-Sectional Study
- Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin
- Prostatic irradiation-induced sexual dysfunction: A review and multidisciplinary guide to management in the radical radiotherapy era (Part III on Psychosexual Therapy and the Masculine Self-Esteem)
- Disproportional signal of sexual dysfunction reports associated with finasteride use in young men with androgenetic alopecia: A pharmacovigilance analysis of VigiBase
- Practical Geriatrics: Maintaining Sexual Health After Menopause
- Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men
- Risk assessment of the top 60 drugs for drug-related sexual dysfunction: a disproportion analysis from the Food and Drug Administration adverse event reporting system
- Ejaculatory dysfunction in the treatment of lower urinary tract symptoms
- Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia
- Testosterone Treatment in Women – An Overview
- Sexual Dysfunctions Related to Drugs Used in the Management of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Narrative Review on α-Blockers and 5-Alpha Reductase Inhibitors
- The Impact of the 5α-Reductase Inhibitors (5α-RIs) on Male Sexual Function and Psychological Well-Being
- Clinical Evaluation of Women Presenting with Low Libido and Determination of Whether Androgen Therapy Might Be Appropriate
- Sexual Dysfunction in Polycystic Ovary Syndrome (PCOS): A Biopsychosocial Approach to Assessment and Management
- Multidimensional assessment of adverse events of finasteride：a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024
- POST-FINASTERIDE SYNDROME AND POST-SSRI SEXUAL DYSFUNCTION: TWO CLINICAL CONDITIONS APPARENTLY DISTANT, BUT VERY CLOSE
- Management of Sexual Dysfunction in Postmenopausal Breast Cancer Patients Taking Adjuvant Aromatase Inhibitor Therapy